The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Viral Vector-Based Therapeutic Cancer Vaccines
Open accessAbstract
Most viruses are naturally immunogenic and can be engineered to express tumor antigen transgenes. Moreover, many types of recombinant viruses have been shown to infect professional antigen-presenting cells, specifically dendritic cells, and express their transgenes. This enhanced presentation of tumor antigens to the immune system has led to an increase in the frequency and avidity of cytotoxic T lymphocytes that target tumor cells expressing the tumor antigen(s) encoded in the vaccine vector. Logistically, recombinant viruses can be produced, administered, and quality controlled more easily compared with other immunotherapy strategies. The intrinsic properties of each virus have distinct advantages and disadvantages, which can determine their applicability in a particular therapeutic setting. The disadvantage of some vectors is the development of host-induced neutralizing antibodies to the vector itself, thus limiting its continued use. The "off-the-shelf" nature of viral vaccine platforms renders them exceptionally suitable for multicenter randomized trials. This review described and discussed the strategies used and results using viral-based vaccines, with emphasis on phases II and III clinical trials. Future directions will involve the evaluation of viral-based vaccines in the adjuvant and neoadjuvant settings, in patients with low burden metastatic disease, and in combination with other forms of therapy including immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taking it a step forward, the co-introduction of tumor antigens along with co-stimulatory molecules in a viral vector seems to be an even more effective way to trigger an effective immune response [157].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,456
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andrès, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,103
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 994
Self-citationHouse, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Tsang, K.-Y., Zaremba, S., Nieroda, C. A., Zhu, M., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marté, J. L., Beetham, P. K., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Self-citationPelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E. S., Pedicano, J. E., Gehan, E. A., Peck, R. A., Arlen, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 356
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 533
Metadata
- Authors
- Larocca, C., & Schlom, J.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- Corresponding author
- Larocca, Cecilia
- Venue
- The Cancer Journal
- Published
- 2011-09
- Volume
- 17
- Issue
- 5
- Pages
- 359-371
- ISSN
- 1528-9117 (ISSN-L)
- PMC
- PMC3207353
- OpenAlex
- W2076096828
- Cited by
- 222
- References
- 85
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 9 · 2015: 17 · 2014: 17 · 2013: 15 · 2012: 5
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Cancer Journal (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Cancer Institute (ZIABC010425)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- viral vector vaccines, therapeutic cancer vaccines, dendritic cells, antigen presentation, cytotoxic T lymphocytes, neutralizing antibodies, recombinant virus, neoadjuvant and adjuvant therapy, metastatic cancer, combination immunotherapy, clinical trials
- MeSH terms
- Antigens, Neoplasm, Clinical Trials as Topic, Genetic Vectors, Humans, Male, Prostatic Neoplasms, Viral Vaccines, Viruses, Vaccines, DNA, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
